In this dose-ranging study , patients ( n = 306 ) with active RA , despite methotrexate , were randomly assigned to placebo or one of five subcutaneous doses/regimens of sarilumab : 100mg q2w , 150mg q2w , 100mg qw , 200mg q2w , 150mg qw for 12weeks , plus methotrexate .